MU
32
-6
NRG
50
-2
SWK
56
-6
T
48
3
KO
44
2
FOX
57
-3
DVN
29
4
STI
31
19
MLM
57
-3
VZ
42
3
PDCO
30
-6
SLB
56
-3
CVX
38
6
NSC
64
2
RIG
44
-2
NTAP
61
-3
URBN
66
2
DTE
38
-4
SIG
47
-2
AON
60
2
MU
32
-6
NRG
50
-2
SWK
56
-6
T
48
3
KO
44
2
FOX
57
-3
DVN
29
4
STI
31
19
MLM
57
-3
VZ
42
3
PDCO
30
-6
SLB
56
-3
CVX
38
6
NSC
64
2
RIG
44
-2
NTAP
61
-3
URBN
66
2
DTE
38
-4
SIG
47
-2
AON
60
2
Financhill
Back

Cytokinetics 10K Form

Buy
53

CYTK
Cytokinetics

Last Price:
54.71
Seasonality Move:
9.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-10 10Q CYTK/Cytokinetics Quarterly
2023-11-03 10Q CYTK/Cytokinetics Quarterly
2023-08-03 10Q CYTK/Cytokinetics Quarterly
2023-05-05 10Q CYTK/Cytokinetics Quarterly
2022-11-04 10Q CYTK/Cytokinetics Quarterly
2022-08-05 10Q CYTK/Cytokinetics Quarterly

Receive CYTK News And Ratings

See the #1 stock for the next 7 days that we like better than CYTK

CYTK Financial Statistics

Sales & Book Value

Annual Sales: $7.53M
Cash Flow: $-102.2M
Price / Cash Flow: 0
Annual Sales: $-0.12
Price / Book: 0

Profitability

EPS (TTM): -5.38000
Net Income (TTM): $-576.4M
Gross Margin: $-322.59M
Return on Equity: 0%
Return on Assets: -54.04%

Cytokinetics Earnings Forecast

Key Cytokinetics Financial Ratios

  • The Gross Profit Margin over the past 18 years for CYTK is -4,284.10%.
  • The Selling, General & Administrative Expenses for CYTK have been equal to 2,305.60% of Gross Profit Margin.
  • The Research & Development expenses have been 227.10% of Revenue.
  • The Interest Expense is -10.96% of Operating Income.
  • The Net Earning history of CYTK is -6,988.63% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 12 years.

Cytokinetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYTK
CUSIP: 23282W
Website: cytokinetics.com

Debt

Debt-to-Equity Ratio: -47.16
Current Ratio: 9.28
Quick Ratio: 9.22

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTK Technical Analysis vs Fundamental Analysis

Buy
53
Cytokinetics (CYTK) is a Buy

Is Cytokinetics a Buy or a Sell?

  • Cytokinetics stock is rated a Buy
    The current Cytokinetics [CYTK] share price is $55.95. The Score for CYTK is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.